A staged phase 1 study of the treatment of malignant glioma with G207, a genetically engineered HSV-1 [herpes simplex 1], followed by radiation therapy
Phase of Trial: Phase I/II
Latest Information Update: 21 Dec 2013
At a glance
- Drugs G 207 (Primary)
- Indications Glioma
- Focus Adverse reactions
- 17 Oct 2005 New trial record.